Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform study of multiple therapies for multiple myeloma
MOH_2024-02-29_013035Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cevostamab and iberdomide in multiple myeloma (MM), sponsored by Roche. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
cevostamabiberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2024-02-29_013035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-29_013035.